Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas

Preventive Medicine

Volumn 80, Issue , 2015, Pages 18-22

  Meyer, Marjorie ^a   Phillips, Julie ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Buprenorphine; Methadone; Opioid dependence; Pregnancy; Rural

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRENORPHINE; LEVACETYLMETHADOL; METHADONE; NALOXONE; NALTREXONE;

ARTICLE; COMMUNITY CARE; DETOXIFICATION; DRUG HALF LIFE; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MATERNAL CARE; OPIATE ADDICTION; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; QT PROLONGATION; RURAL AREA; UNITED STATES; ADULT; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; HEALTH CENTER; INFANT; NEWBORN; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS; RURAL HEALTH CARE; VERMONT;

ADULT; BUPRENORPHINE; COMMUNITY HEALTH CENTERS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT; INFANT, NEWBORN; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RURAL HEALTH SERVICES; VERMONT;

EID: 84942553994     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2015.07.015     Document Type: Article

References (44)

1. American Association for the Treatment of Opioid Dependence Increasing access to medication to treat opioid addiction-increasing access for the treatment of opioid addiction with medications (Accessed 4-15-2015). http://www.aatod.org/wp-content/uploads/2014/07/MAT-Policy-Paper-FINAL-070214-2.pdf.
2. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J. Addict. Dis. 2012, 31:207-225.
3. Bonhomme J., Shim R.S., Gooden R., Tyus D., Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J. Natl. Med. Assoc. 2012, 104:342-350.
4. Buckley V., Abdalvahed R., Haber P. Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service. Aust. NZ J. Obstet. Gynecol. 2013, 53:464-470.
5. Cicero T.J., Ellis M.S., Surratt H.L., Kurtz S.P. The changing face of heroin use in the United States: a retrospective analysis of the past 50years. JAMA psychiatry 2014, 71:821-826.
6. Connery H.S. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv. Rev. Psychiatry 2015, 23:63-75.
7. DeFlavio J.R., Rolin S.A., Nordstrom B.R., Kazal L.A. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015, 15:3019.
8. Evans E., Li L., Min J., Huang D., Urada D., Liu L., Hser Y.I., Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction 2015, 110:996-1005.
9. Fiellin D.A., Schottenfeld R.S., Cutter C.J., Moore B.A., Barry D.T., O'Connor P.G. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern. Med. 2014, 174:1947-1954.
10. Finnegan L.P. Management of pregnant drug dependent women. NYAS 1978, 311:135-146.
11. Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000, 95:239-244.
12. Gaglio B., Shoup J.A., Glasgow R.E. The RE-AIM framework: a systematic review of use over time. Am. J. Public Health 2013, 103:e38-e46.
13. Hall G., Neighbors C.J., Iheoma J., Dauber S., Adams M., Culleton R., Muench F., Borys S., McDonald R., et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J. Subst. Abus. Treat. 2014, 46:511-515.
14. Holbrook A.M., Jones H.E., Heil S.H., Martin P.R., Stine S.M., Fischer G., Coyle M.G., Kaltenbach K. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug Alcohol Depend. 2013, 132:329-334.
15. Hutchinson E., Catlin M., Andrilla C.H., Baldwin L.M., Rosenblatt R.A. Barriers to primary care physicians prescribing buprenorphine. Ann. Fam. Med. 2014, 12:128-133.
16. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., O'Grady K.E., Selby P., Martin P.R., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331.
17. Jones H.E., Finnegan L.P., Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012, 72:747-757.
18. Jones H.E., Chisolm M.S., Jansson L.M., Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction 2013, 108:233-247.
19. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377:1506-1513.
20. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, CD002209.
21. Meyer M., Benvenuto A., Howard D., Johnston A., Plante D., Metayer J., Mandell T. Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome. J. Addict. Med. 2012, 6:124-130.
22. Meyer M.C., Johnston A.M., Crocker A.M., Heil S.H. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J. Addict. Med. 2015, 9:81-86.
23. Monte A.A., Mandell T., Wilford B.B., Tennyson J., Boyer E.W. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J. Addict. Dis. 2009, 28:226-231.
24. National Institute of Health National consensus development panel on effective medical treatment of opiate addiction. JAMA 1998, 280:1936-1943.
25. Orman J.S., Keating G.M. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009, 69:577-607.
26. Patrick S.W., Schumacher R.E., Benneyworth B.D., Krans E.E., McAllister J.M., Davis M.M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. Jama 2012, 307:1934-1940.
27. Peles E., Schreiber S., Adelson M. Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry. J. Addict. Med. 2013, 7:177-182.
28. Reisinger M. Treatment of four pregnant heroin addicts with buprenorphine: history and outcome. NIDA Research Monograph No. 162 1995, 261. US Government Printing Office Washington, DC. L.S. Harris (Ed.).
29. SAMHSA Medication-assisted treatment for opioid addiction in opioid treatment programs: a treatment improvement protocol, TIP 43 (Accessed 7-6-2015). http://store.samhsa.gov/shin/content//SMA12-4214/SMA12-4214.pdf.
30. SAMHSA Results from the 2013 National Survey on Drug Use and Health: detailed tables in NSDUH 2013, SAMSHA, Center for Behavioral Health Statistics and Quality, Rockville, MD, (http://www.samhsa.gov/data/population-data-nsduh/reports?tab=32. Accessed 4-15-2015).
31. SAMHSA Buprenorphine waiver (Accessed 4-15-2015). http://buprenorphine.samhsa.gov/waiver_qualifications.htmlref%20waiver.
32. SAMHSA Opioid use in pregnancy: a community's approach, the Children and Recovering Mothers (CHARM) collaborative (Accessed 12-22-2014). https://www.ncsacw.samhsa.gov/resources/resources-mat.aspx.
33. Schuman-Olivier Z., Hoeppner B.B., Weiss R.D., Borodovsky J., Shaffer H.J., Albanese M.J. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend. 2013, 132:580-586.
34. Sigmon S.C. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry 2014, 71:359-360.
35. Sorensen J.L. From Cat's Cradle to Beat the Reaper: getting evidence-based treatments into practice in spite of ourselves. Addict. Behav. 2011, 36:597-600.
36. Stewart R.D., Nelson D.B., Adhikari E.H., McIntire D.D., Roberts S.W., Dashe J.S., Sheffield J.S. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am. J. Obstet. Gynecol. 2013, 209(267):e1-e5.
37. Stotts A.L., Dodrill C.L., Kosten T.R. Opioid dependence treatment: options in pharmacotherapy. Expert. Opin. Pharmacother. 2009, 10:1727-1740.
38. Vermont Child Health Improvement Program Improving care of the opioid exposed newborn (Accessed 7-6-2015). http://www.uvm.edu/medicine/vchip/?Page=ICON.html.
39. Vermont Department of Health Opioid addiction treatment programs (Accessed 7-6-2015). http://www.leg.state.vt.us/reports/2013ExternalReports/295237.pdf.
40. Vermont Department of Health The challenge of opioid addiction (Accessed 4-15-2015). http://www.healthvermont.gov/adap/treatment/opioids/documents/OpioidChallengeBrief_June2014.pdf.
41. Vermont Department of Health SEOW workgroup: prescription drug misuse in Vermont (Accessed 4-15-2015). http://healthvermont.gov/adap/documents/SEOW_RxIssueBrief_June2014_000.pdf.
42. Vermont Department of Health Increasing access to opioid addiction treatment (Accessed 4-22-2015). http://governor.vermont.gov/sites/governor/files/Access%20to%20Opioid%20Addiction%20Tx%20Report%202014.pdf.
43. Wiegand S.L., Stringer E.M., Stuebe A.M., Jones H., Seashore C., Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet. Gynecol. 2015, 125:363-368.
44. York R.G., Denny K.H., Moody D.E., Alburges M.E. Developmental toxicity of levo-alpha-acetylmethadol (LAAM) in tolerant rats. Int. J. Toxicol. 2002, 21:147-159.